Abstract:O‐linked N ‐acetylglucosamine (O‐GlcNAc) is a highly dynamic post‐translational modification that involves an addition of a single N‐ acetylglucosamine to serine and threonine residue in mitochondria, nuclear and cytoplasmic proteins. O‐GlcNAc cycling is the addition and removal of O‐GlcNAc by O‐GlcNAc transferase (OGT) and O‐GlcNAcase (OGA) respectively. Disruptions in O‐GlcNAc cycling contribute to diseases such as diabetes, cancer, and neurodegeneration. Accumulative dysfunctional mitochondria can also lead to the development of neurodegenerative diseases, and importantly, O‐GlcNAcylation regulates mitochondrial function. Previously, using a proteomics based screen we found that altering the expression of OGT and OGA disrupted mitochondrial protein expression, including proteins involved in the respiratory chain and TCA cycle. Furthermore, mitochondrial morphology in the over‐expressing cells had reduced and disorganized cristae and altered shape and size. Both cellular respiration and glycolysis was impaired in the OGT/OGA gain of function cells. These data suggested that O‐GlcNAc cycling was essential for the proper regulation of mitochondrial function. We hypothesized that prolonged elevations in cellular O‐GlcNAc levels would alter the metabolic profile of the cell. We disrupted O‐GlcNAc cycling by either treating SH‐SY5Y neuroblastoma cells with low levels of Glucosamine (GlcN) or OGA inhibitor Thiamet‐G (TMG). Importantly, the metabolic substrate for O‐GlcNAcylation is UDP‐GlcNAc. UDP‐GlcNAc is synthesized via the hexosamine biosynthetic pathway, which is highly sensitive towards the availability of nutrients in the cellular environment. GlcN feeds into the hexosamine biosynthetic pathway after the first rate‐limiting enzyme GFAT1, glutamine fructose‐6‐phosphate aminotransferase 1, and additional supplementation of GlcN increases O‐GlcNAcylation via elevating the synthesis of UDP‐GlcNAc. We found that prolonged TMG/GlcN treatment improved mitochondrial function. In the TMG/GlcN treated cells, reactive oxygen species (ROS) production was significantly reduced. Interestingly, the protein expression of the mitochondrial antioxidant, manganese superoxide dismustase (MnSOD) was lower. Additionally, ATP production was lower in these TMG/GlcN treated cells. Furthermore, we found that mitochondrial were longer in shape and mitochondrial fusion/fission protein expressions were decreased. Altogether, these data demonstrated that prolonged alterations to the cellular homeostasis of O‐GlcNAc levels improve mitochondrial function likely through reprogramming of metabolic transcriptional programs. Further understanding of how O‐GlcNAc cycling regulates metabolism will provide new insights into metabolic diseases such as cancer and Alzheimer's. Support or Funding Information RO1DK100595

O-GlcNAc impacts mitophagy via the PINK1-dependent pathway

Thiamme2-G, a Novel O-GlcNAcase Inhibitor, Reduces Tau Hyperphosphorylation and Rescues Cognitive Impairment in Mice

Impact of O-GlcNAcylation elevation on mitophagy and glia in the dentate gyrus

O‐GlcNAc is Critical for the Regulation of Energy Metabolism

O-GlcNAcylation ameliorates the pathological manifestations of Alzheimer’s disease by inhibiting necroptosis

Mitophagy coordination with retrograde transport ensures the integrity of synaptic mitochondria

The Role of Mitophagy in the Regulation of Mitochondrial Energetic Status in Neurons

Elevated O‐GlcNAcylation levels improve mitochondrial function

Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer’s disease

Effect of Alternating Nicotinamide Phosphoribosyltransferase Expression Levels on Mitophagy in Alzheimer's Disease Mouse Models

Acute increase of protein O-GlcNAcylation in mice leads to transcriptome changes in the brain opposite to what is observed in Alzheimer's Disease

Acute increase of protein O-GlcNAcylation in mice leads to transcriptome changes in the brain opposite to what is observed in Alzheimer Disease

Nutrient-drivenO-GlcNAc Cycling Influences Autophagic Flux and Neurodegenerative Proteotoxicity

Defining the Dynamic Regulation of O-GlcNAc Proteome in the Mouse Cortex---the O-GlcNAcylation of Synaptic and Trafficking Proteins Related to Neurodegenerative Diseases

GSAP Regulates Mitochondrial Function Through the Mitochondria-associated ER Membrane in the Pathogenesis of Alzheimer’s Disease

The KEAP1/PGAM5/AIFM1-Mediated oxeiptosis pathway in Alzheimer's disease

Mitochondrial bioenergetics stimulates autophagy for pathological MAPT/Tau clearance in tauopathy neurons

O-GlcNAcylation is essential for therapeutic mitochondrial transplantation

Dysfunctional Mitochondria and Mitophagy as Drivers of Alzheimer's Disease Pathogenesis

The potential benefits of PGC-1α in treating Alzheimer's disease are dependent on the integrity of the LLKYL L3 motif: Effect of regulating mitochondrial axonal transportation

Ginsenoside Rg1 Ameliorates Alzheimer's Disease Pathology Via Restoring Mitophagy